Literature DB >> 19228620

Quality of life after late invasive therapy for occluded arteries.

Daniel B Mark1, Wenqin Pan, Nancy E Clapp-Channing, Kevin J Anstrom, John R Ross, Rebecca S Fox, Gerard P Devlin, C Edwin Martin, Christopher Adlbrecht, Patricia A Cowper, Linda Davidson Ray, Eric A Cohen, Gervasio A Lamas, Judith S Hochman.   

Abstract

BACKGROUND: The open-artery hypothesis postulates that late opening of an infarct-related artery after myocardial infarction will improve clinical outcomes. We evaluated the quality-of-life and economic outcomes associated with the use of this strategy.
METHODS: We compared percutaneous coronary intervention (PCI) plus stenting with medical therapy alone in high-risk patients in stable condition who had a totally occluded infarct-related artery 3 to 28 days after myocardial infarction. In 951 patients (44% of those eligible), we assessed quality of life by means of a battery of tests that included two principal outcome measures, the Duke Activity Status Index (DASI) (which measures cardiac physical function on a scale from 0 to 58, with higher scores indicating better function) and the Medical Outcomes Study 36-Item Short-Form Mental Health Inventory 5 (which measures psychological well-being). Structured quality-of-life interviews were performed at baseline and at 4, 12, and 24 months. Costs of treatment were assessed for 458 of 469 patients in the United States (98%), and 2-year cost-effectiveness was estimated.
RESULTS: At 4 months, the medical-therapy group, as compared with the PCI group, had a clinically marginal decrease of 3.4 points in the DASI score (P=0.007). At 1 and 2 years, the differences were smaller. No significant differences in psychological well-being were observed. For the 469 patients in the United States, cumulative 2-year costs were approximately $7,000 higher in the PCI group (P<0.001), and the quality-adjusted survival was marginally longer in the medical-therapy group.
CONCLUSIONS: PCI was associated with a marginal advantage in cardiac physical function at 4 months but not thereafter. At 2 years, medical therapy remained significantly less expensive than routine PCI and was associated with marginally longer quality-adjusted survival. (ClinicalTrials.gov number, NCT00004562.) 2009 Massachusetts Medical Society

Entities:  

Mesh:

Year:  2009        PMID: 19228620      PMCID: PMC2724193          DOI: 10.1056/NEJMoa0805151

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  13 in total

1.  Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.

Authors:  D B Mark; R A Harrington; A M Lincoff; R M Califf; C L Nelson; A A Tsiatis; H Buell; K W Mahaffey; L Davidson-Ray; E J Topol
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

2.  Medical economics and the assessment of value in cardiovascular medicine: Part I.

Authors:  Daniel B Mark; Mark A Hlatky
Journal:  Circulation       Date:  2002-07-23       Impact factor: 29.690

Review 3.  Measurement of health state utilities for economic appraisal.

Authors:  G W Torrance
Journal:  J Health Econ       Date:  1986-03       Impact factor: 3.883

4.  Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

Authors:  Daniel B Mark; Charlotte L Nelson; Kevin J Anstrom; Sana M Al-Khatib; Anastasios A Tsiatis; Patricia A Cowper; Nancy E Clapp-Channing; Linda Davidson-Ray; Jeanne E Poole; George Johnson; Jill Anderson; Kerry L Lee; Gust H Bardy
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

5.  Design and methodology of the Occluded Artery Trial (OAT).

Authors:  Judith S Hochman; Gervasio A Lamas; Genell L Knatterud; Christopher E Buller; Vladimir Dzavik; Daniel B Mark; Harmony R Reynolds; Harvey D White
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

6.  A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index).

Authors:  M A Hlatky; R E Boineau; M B Higginbotham; K L Lee; D B Mark; R M Califf; F R Cobb; D B Pryor
Journal:  Am J Cardiol       Date:  1989-09-15       Impact factor: 2.778

7.  Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators.

Authors:  M A Hlatky; W J Rogers; I Johnstone; D Boothroyd; M M Brooks; B Pitt; G Reeder; T Ryan; H Smith; P Whitlow; R Wiens; D B Mark
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

8.  Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial.

Authors: 
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

9.  Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME).

Authors:  Matthias Pfisterer
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

10.  Quality of life with defibrillator therapy or amiodarone in heart failure.

Authors:  Daniel B Mark; Kevin J Anstrom; Jie L Sun; Nancy E Clapp-Channing; Anastasios A Tsiatis; Linda Davidson-Ray; Kerry L Lee; Gust H Bardy
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

View more
  13 in total

1.  Quality of life effects of automatic external defibrillators in the home: results from the Home Automatic External Defibrillator Trial (HAT).

Authors:  Daniel B Mark; Kevin J Anstrom; Steven E McNulty; Greg C Flaker; Andrew M Tonkin; Warren M Smith; William D Toff; Paul Dorian; Nancy E Clapp-Channing; Jill Anderson; George Johnson; Eleanor B Schron; Jeanne E Poole; Kerry L Lee; Gust H Bardy
Journal:  Am Heart J       Date:  2010-04       Impact factor: 4.749

2.  Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT).

Authors:  Gerard Devlin; Harmony R Reynolds; Daniel B Mark; James M Rankin; Antonio C Carvalho; Carlos Vozzi; George Sopko; Paulo Caramori; Vladimir Džavík; Michael Ragosta; Sandra A Forman; Gervasio A Lamas; Judith S Hochman
Journal:  Am Heart J       Date:  2011-01       Impact factor: 4.749

Review 3.  Secondary prevention of ischaemic cardiac events.

Authors:  Jane S Skinner; Angela Cooper
Journal:  BMJ Clin Evid       Date:  2011-08-30

4.  Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.

Authors:  Maria Mori Brooks; Sheng-Chia Chung; Tarek Helmy; William B Hillegass; Jorge Escobedo; Kathryn A Melsop; Elaine M Massaro; Robert D McBane; Pamela Hyde; Mark A Hlatky
Journal:  Circulation       Date:  2010-10-11       Impact factor: 29.690

5.  Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction.

Authors:  Judith S Hochman; Harmony R Reynolds; Vladimír Dzavík; Christopher E Buller; Witold Ruzyllo; Zygmunt P Sadowski; Aldo P Maggioni; Antonio C Carvalho; James M Rankin; Harvey D White; Suzanne Goldberg; Sandra A Forman; Daniel B Mark; Gervasio A Lamas
Journal:  Circulation       Date:  2011-10-24       Impact factor: 29.690

6.  The trial to assess chelation therapy 2 (TACT2): Rationale and design.

Authors:  Gervasio A Lamas; Kevin J Anstrom; Ana Navas-Acien; Robin Boineau; Hwasoon Kim; Yves Rosenberg; Mario Stylianou; Teresa L Z Jones; Bonnie R Joubert; Regina M Santella; Esteban Escolar; Y Wady Aude; Vivian Fonseca; Thomas Elliott; Eldrin F Lewis; Michael E Farkouh; David M Nathan; Ana C Mon; Leigh Gosnell; Jonathan D Newman; Daniel B Mark
Journal:  Am Heart J       Date:  2022-05-19       Impact factor: 5.099

7.  Safer cardiac surgery.

Authors:  Alan F Merry
Journal:  J Extra Corpor Technol       Date:  2009-12

8.  Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial.

Authors:  Daniel B Mark; J David Knight; Eric J Velazquez; Jonathan G Howlett; John A Spertus; Ljubomir T Djokovic; Tina M Harding; Gena R Rankin; Laura A Drew; Bozena Szygula-Jurkiewicz; Christopher Adlbrecht; Kevin J Anstrom
Journal:  Am Heart J       Date:  2009-04-01       Impact factor: 4.749

9.  Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction.

Authors:  Christopher Adlbrecht; Kurt Huber; Harmony R Reynolds; Antonio C Carvalho; Vladimír Džavík; Philippe Gabriel Steg; Li Liu; Paolo Marino; Camille A Pearte; James M Rankin; Harvey D White; Gervasio A Lamas; Judith S Hochman
Journal:  Int J Cardiol       Date:  2014-03-28       Impact factor: 4.164

Review 10.  Assessing quality-of-life outcomes in cardiovascular clinical research.

Authors:  Daniel B Mark
Journal:  Nat Rev Cardiol       Date:  2016-02-18       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.